Magnitude of the Difference Between Clinic and Ambulatory Blood Pressures and Risk of Adverse Outcomes in Patients With Chronic Kidney Disease. [PDF]
, 2019 Background Obtaining 24-hour ambulatory blood pressure ( BP ) is recommended for the detection of masked or white-coat hypertension. Our objective was to determine whether the magnitude of the difference between ambulatory and clinic BP s has prognostic ...
Bae, Se Ri +7 more
core +1 more source
Landscape of BRAF transcript variants in human cancer
Molecular Oncology, EarlyView.We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda +5 more
wiley +1 more source
The restricted mean survival time as a replacement for the hazard ratio and the number needed to treat in long-term studies. [PDF]
ESC Heart Fail, 2021 Messori A, Bartoli L, Trippoli S.
europepmc +1 more source
Assessing and improving the reliability of meta-analyses of hazard ratios derived from published time-to-event data [PDF]
, 2013 Jayne F. Tierney +4 more
openalex +1 more source
Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer
Molecular Oncology, EarlyView.G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren +16 more
wiley +1 more source
Time dependent hazard ratio estimation using instrumental variables without conditioning on an omitted covariate. [PDF]
BMC Med Res Methodol, 2021 MacKenzie TA +2 more
europepmc +1 more source
Hazard ratio: cuando el riesgo varía a lo largo del tiempo [PDF]
, 2015 Manuel Molina Arias
openalex +1 more source
Molecular Oncology, EarlyView.In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton +17 more
wiley +1 more source
Intake Biomarkers for Nutrition and Health: Review and Discussion of Methodology Issues
MetabolitesMetabolomics profiles from blood, urine, or other body fluids have the potential to assess intakes of foods and nutrients objectively, thereby strengthening nutritional epidemiology research.
Ross L. Prentice
doaj +1 more source
Using the geometric average hazard ratio in sample size calculation for time-to-event data with composite endpoints. [PDF]
BMC Med Res Methodol, 2021 Cortés Martínez J +3 more
europepmc +1 more source